<DOC>
	<DOCNO>NCT01159249</DOCNO>
	<brief_summary>This study design demonstrate long-term safety vildagliptin patient type 2 diabetes . This study study vildagliptin add-on therapy metformin , thiazolidinedione , α-glucosidase inhibitor ( α-GI ) , rapid-acting insulin secretagogues treatment type 2 diabetes Japan .</brief_summary>
	<brief_title>Long-term Safety Study Vildagliptin Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>patient type 2 diabetes inadequately control diet , exercise metformin , thiazolidinedione , αGI , glinides monotherapy Age 20 year inclusive HbA1c range ≥ 6.5 ≤ 10 % Type 1 diabetes mellitus , diabetes result pancreatic injury , secondary form diabetes Significant heart diseases Significant diabetic complication</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vildagliptin , Type 2 Diabetes , HbA1c , Fasting Plasma Glucose , Long-Term Safety</keyword>
</DOC>